{"disease":{"id":"urticaria","name":"Urticaria","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":29,"pipeline_drug_count":0,"trial_count":10},"drugs":{"marketed":[{"drug_id":"omalizumab","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xolair","generic_name":"omalizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Ig epsilon chain C region","drug_class":"Anti-IgE [EPC]","quality_score":52,"revenue":"3200","mechanism":null},{"drug_id":"alimemazine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Temaril","generic_name":"alimemazine","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"trimeprazine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"alimemazine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Temaril","generic_name":"alimemazine","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"trimeprazine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"bamipine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bamipin","generic_name":"BAMIPINE","company_name":"","drug_phase":"phase_2","molecular_target":"Histamine H1 receptor","drug_class":"bamipine","quality_score":28,"revenue":null,"mechanism":"Bamipine blocks histamine at the H1 receptor to treat urticaria."},{"drug_id":"doxylamin","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxylamin","company_name":"St. Petersburg Bekhterev Research Psychoneurological Institute","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"doxylamin","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxylamin","company_name":"St. Petersburg Bekhterev Research Psychoneurological Institute","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"bilastin","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bilastin","company_name":"Charite University, Berlin, Germany","drug_phase":"phase_3","molecular_target":"Histamine H1 receptor","drug_class":"","quality_score":4,"revenue":null,"mechanism":null},{"drug_id":"rupatadine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rupax","generic_name":"RUPATADINE","company_name":"Teikoku Seiyaku","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"rupatadine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexbrompheniramine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drixoral","generic_name":"DEXBROMPHENIRAMINE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dexbrompheniramine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"dexbrompheniramine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drixoral","generic_name":"DEXBROMPHENIRAMINE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dexbrompheniramine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"diphenylpyraline","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hispril","generic_name":"DIPHENYLPYRALINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"diphenylpyraline","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"diphenylpyraline","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hispril","generic_name":"DIPHENYLPYRALINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"diphenylpyraline","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"tripelennamine-citrate","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyribenzamin","generic_name":"TRIPELENNAMINE CITRATE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"tripelennamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tripelennamine-citrate","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyribenzamin","generic_name":"TRIPELENNAMINE CITRATE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"tripelennamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mepyramine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrilamine","generic_name":"mepyramine","company_name":"Impax Labs","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"mepyramine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrilamine","generic_name":"mepyramine","company_name":"Impax Labs","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"antazoline","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenazoline","generic_name":"ANTAZOLINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"antazoline","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"antazoline","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenazoline","generic_name":"ANTAZOLINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"antazoline","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"chlorpheniramine-maleate","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tussionex Pennkinetic","generic_name":"CHLORPHENIRAMINE MALEATE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"chlorpheniramine-maleate","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tussionex Pennkinetic","generic_name":"CHLORPHENIRAMINE MALEATE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"emedastine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emadine","generic_name":"EMEDASTINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Inhibitor","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxyzine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxyzine Hydrochloride","generic_name":"HYDROXYZINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxyzine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxyzine Hydrochloride","generic_name":"HYDROXYZINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"levocetirizine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xyzal","generic_name":"LEVOCETIRIZINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"fexofenadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allegra","generic_name":"fexofenadine","company_name":"Generic (originally Hoechst Marion Roussel/Sanofi)","drug_phase":"marketed","molecular_target":"Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor","drug_class":"Second-generation antihistamine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"cyproheptadine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyproheptadine Hydrochloride","generic_name":"CYPROHEPTADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"cyproheptadine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cyproheptadine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyproheptadine Hydrochloride","generic_name":"CYPROHEPTADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"cyproheptadine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"doxylamine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unisom","generic_name":"DOXYLAMINE","company_name":"Chattem","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Antihistamine","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"doxylamine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unisom","generic_name":"DOXYLAMINE","company_name":"Chattem","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Antihistamine","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"bilastine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bellozal","generic_name":"BILASTINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"bilastine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"terfenadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seldane","generic_name":"TERFENADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"High Risk QT Prolonging Agents","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"astemizole","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hismanal","generic_name":"ASTEMIZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"pecazine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pecazine","company_name":"","drug_phase":"unknown","molecular_target":"5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cetirizine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyrtec","generic_name":"cetirizine","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Angiopoietin-1 receptor, Histamine H1 receptor, Potassium voltage-gated channel subfamily H member 2","drug_class":"Second-generation antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pecazine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pecazine","company_name":"","drug_phase":"unknown","molecular_target":"5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rupatadin","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rupatadin","company_name":"Marcus Maurer","drug_phase":"phase_2","molecular_target":"Platelet-activating factor receptor, Histamine H1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"xolair","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xolair","company_name":"Taizhou Mabtech Pharmaceutical Co.,Ltd","drug_phase":"marketed","molecular_target":"Ig epsilon chain C region","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"desloratadine","indication_name":"Allergic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clarinex","generic_name":"desloratadine","company_name":"Generic (originally Schering-Plough/MSD)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"Histamine-1 Receptor Antagonist [EPC]","quality_score":54,"revenue":null,"mechanism":"Active metabolite of loratadine with higher potency at H1 receptors and additional anti-inflammatory properties."},{"drug_id":"desloratadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clarinex","generic_name":"desloratadine","company_name":"Generic (originally Schering-Plough/MSD)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"Histamine-1 Receptor Antagonist [EPC]","quality_score":54,"revenue":null,"mechanism":"Active metabolite of loratadine with higher potency at H1 receptors and additional anti-inflammatory properties."},{"drug_id":"loratadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claritin","generic_name":"loratadine","company_name":"Generic (originally Schering-Plough)","drug_phase":"marketed","molecular_target":"Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1","drug_class":"Second-generation antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"methapyrilene","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thenylene","generic_name":"METHAPYRILENE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"methapyrilene","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thenylene","generic_name":"METHAPYRILENE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"promethazine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenergan","generic_name":"promethazine","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR","drug_class":"Phenothiazine antihistamine/antiemetic","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"ebastine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bastel","generic_name":"EBASTINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"ebastine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"dexchlorpheniramine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexchlorpheniramine Maleate","generic_name":"DEXCHLORPHENIRAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dexchlorpheniramine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dexchlorpheniramine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexchlorpheniramine Maleate","generic_name":"DEXCHLORPHENIRAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dexchlorpheniramine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chlorphenamine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tussionex Pennkinetic","generic_name":"chlorphenamine","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"chlorphenamine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tussionex Pennkinetic","generic_name":"chlorphenamine","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolone-acetate","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Medrol","generic_name":"METHYLPREDNISOLONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response."},{"drug_id":"triprolidine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Actidil","generic_name":"TRIPROLIDINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"triprolidine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"triprolidine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Actidil","generic_name":"TRIPROLIDINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"triprolidine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"brompheniramine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dimetane-Dx","generic_name":"BROMPHENIRAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"brompheniramine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"brompheniramine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dimetane-Dx","generic_name":"BROMPHENIRAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"brompheniramine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe chronic spontaneous urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe chronic spontaneous urticaria in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"carbinoxamine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Karbinal Er","generic_name":"CARBINOXAMINE","company_name":"Mcneil","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":70,"revenue":null,"mechanism":"Karbinal Er works by blocking the histamine H1 receptor, a key player in the body's allergic response."},{"drug_id":"carbinoxamine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Karbinal Er","generic_name":"CARBINOXAMINE","company_name":"Mcneil","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":70,"revenue":null,"mechanism":"Karbinal Er works by blocking the histamine H1 receptor, a key player in the body's allergic response."},{"drug_id":"azatadine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azatidine","generic_name":"AZATADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"azatadine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"azatadine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azatidine","generic_name":"AZATADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"azatadine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"clemastine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavist","generic_name":"CLEMASTINE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"clemastine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clemastine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavist","generic_name":"CLEMASTINE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"clemastine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxizine","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxizine","company_name":"King Faisal Specialist Hospital & Research Center","drug_phase":"phase_1","molecular_target":"5-hydroxytryptamine receptor 2A, Cytochrome P450 2D6, D(2) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxizine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxizine","company_name":"King Faisal Specialist Hospital & Research Center","drug_phase":"phase_1","molecular_target":"5-hydroxytryptamine receptor 2A, Cytochrome P450 2D6, D(2) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"clemastin","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clemastin","company_name":"Technical University of Munich","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Cytochrome P450 2C19, Solute carrier family 22 member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"clemastin","indication_name":"Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clemastin","company_name":"Technical University of Munich","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Cytochrome P450 2C19, Solute carrier family 22 member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Transfusion Reaction Urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"desloratadin","indication_name":"Allergic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Desloratadin","company_name":"Max Zeller Soehne AG","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone-phosphate","indication_name":"Urticarial transfusion reactions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"desloratadin","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Desloratadin","company_name":"Max Zeller Soehne AG","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":81,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03656939","title":"A Safety Study For Prevenar 13 Among Chinese Children","phase":"","overall_status":"COMPLETED","enrollment_count":21240,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07450170","title":"A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China","phase":"","overall_status":"COMPLETED","enrollment_count":3485,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07358364","title":"Remibrutinib in Real-world Clinical Practice","phase":"","overall_status":"RECRUITING","enrollment_count":3280,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03580356","title":"A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1078,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03580369","title":"A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1072,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04210843","title":"Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1033,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07021495","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","phase":"","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT00852943","title":"Screening Protocol for Genetic Diseases of Allergic Inflammation","phase":"","overall_status":"COMPLETED","enrollment_count":824,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05330637","title":"Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04584190","title":"Real Life Use of Omalizumab in Chronic Urticaria","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05513001","title":"An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":696,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03101618","title":"Animal Allergy in Korean Pet Owners, Pet-related Industry Workers, and Laboratory Animal Reseachers","phase":"","overall_status":"COMPLETED","enrollment_count":643,"lead_sponsor_name":"Gachon University Gil Medical Center","has_results":false},{"nct_id":"NCT04426890","title":"To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":634,"lead_sponsor_name":"Celltrion","has_results":true},{"nct_id":"NCT04976192","title":"Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"Teva Pharmaceuticals USA","has_results":true},{"nct_id":"NCT06210698","title":"Angioedema Biomarker Research Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Foundation For Rare Disease Research","has_results":false},{"nct_id":"NCT05774639","title":"Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Kashiv BioSciences, LLC","has_results":false},{"nct_id":"NCT07358780","title":"Remibrutinib in Real-world Clinical Practice - a US Sub-study","phase":"","overall_status":"RECRUITING","enrollment_count":505,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02626221","title":"A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)","phase":"","overall_status":"COMPLETED","enrollment_count":497,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06042478","title":"Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":470,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05030311","title":"A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":470,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03410290","title":"Journey of Patients With Vasculitis From First Symptom to Diagnosis","phase":"","overall_status":"COMPLETED","enrollment_count":456,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT05032157","title":"A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":455,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06396026","title":"A Study of Efficacy and Safety of TLL-018 in CSU Participants","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":436,"lead_sponsor_name":"Hangzhou Highlightll Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06755424","title":"GI Symptoms in Infants Fed Goat Milk-based Infant Formula","phase":"","overall_status":"COMPLETED","enrollment_count":425,"lead_sponsor_name":"Ausnutria Hyproca B.V.","has_results":false},{"nct_id":"NCT03328897","title":"Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":418,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06063044","title":"Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children","phase":"","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07316114","title":"A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06868212","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04180488","title":"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":397,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT06365879","title":"To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"Taizhou Mabtech Pharmaceutical Co.,Ltd","has_results":false},{"nct_id":"NCT02477332","title":"Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":382,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05976243","title":"A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":362,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07408219","title":"A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients","phase":"","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02161562","title":"OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03926611","title":"This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":311,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02935699","title":"Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":262,"lead_sponsor_name":"JDP Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03991845","title":"A Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":262,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT06250400","title":"Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":252,"lead_sponsor_name":"Hangzhou Grand Biologic Pharmaceutical, Inc.","has_results":false},{"nct_id":"NCT00199238","title":"Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":248,"lead_sponsor_name":"J. Uriach and Company","has_results":false},{"nct_id":"NCT01916967","title":"An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":239,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT04109313","title":"An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02649218","title":"A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05368285","title":"A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT02392624","title":"A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":206,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT06228560","title":"Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"Longbio Pharma","has_results":false},{"nct_id":"NCT07219615","title":"A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04938700","title":"Study on the Correlation Between Intestinal Microecology and Allergic Diseases in Children","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07328178","title":"Analysis of the Role of IgE Proteoforms in Health and Disease","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"KU Leuven","has_results":false},{"nct_id":"NCT05405660","title":"A Study of CDX-0159 in Patients With Chronic Inducible Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT04833855","title":"Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":183,"lead_sponsor_name":"Amgen","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}